Table 2 Characteristics of the training and validation cohorts.
Variables | train (N = 255) | validation (N = 102) | p |
|---|---|---|---|
Voriconazole | |||
No | 176 (69%) | 77 (75.5%) | 0.277 |
Yes | 79 (31%) | 25 (24.5%) | |
Maintenance dose | |||
50 mg q12h | 187 (73.3%) | 77 (75.5%) | 0.775 |
100 mg q12h | 68 (26.7%) | 25 (24.5%) | |
Treatment duration (Mean ± SD) | 9.7 ± 4.7 | 9.8 ± 5.6 | 0.905 |
Malignant tumor | |||
No | 215 (84.3%) | 87 (85.3%) | 0.945 |
Yes | 40 (15.7%) | 15 (14.7%) | |
Sepsis shock | |||
No | 194 (76.1%) | 75 (73.5%) | 0.712 |
Yes | 61 (23.9%) | 27 (26.5%) | |
ICU admission | |||
No | 90 (35.3%) | 35 (34.3%) | 0.958 |
Yes | 165 (64.7%) | 67 (65.7%) | |
Intra abdomen infection | |||
No | 228 (89.4%) | 90 (88.2%) | 0.893 |
Yes | 27 (10.6%) | 12 (11.8%) | |
